Discovery and Engineering of an Aldehyde Tolerant 2-deoxy-D-ribose 5-phosphate Aldolase (DERA) from *Pectobacterium atrosepticum*

Meera Haridas [1,†]**, Carolin Bisterfeld** [1,†]**, Le Min Chen** [1]**, Stefan R. Marsden** [1]**, Fabio Tonin** [1]**, Rosario Médici** [1]**, Adolfo Iribarren** [2]**, Elizabeth Lewkowicz** [2]**, Peter-Leon Hagedoorn** [1]**, Ulf Hanefeld** [1,*] **and Eman Abdelraheem** [1,*]

[1] Department of Biotechnology, Delft University of Technology, Van der Maasweg 9, 2629 HZ Delft, The Netherlands; Meera.hds@gmail.com (M.H.); carolin.bisterfeld@hhu.de (C.B.); l.m.chen@student.tudelft.nl (L.M.C.); S.R.Marsden@tudelft.nl (S.R.M.); f.tonin@tudelft.nl (F.T.); romedici@gmail.com (R.M.); p.l.hagedoorn@tudelft.nl (P.-L.H.)

[2] Laboratorio de Biotransformaciones, Department of Science and Technology, CONICET, Universidad Nacional de Quilmes, Roque S. Peña 352, Bernal Este B1876BXD, Argentina; airibarren@unq.edu.ar (A.I.); elewko@unq.edu.ar (E.L.)

* Correspondence: u.hanefeld@tudelft.nl (U.H.); e.m.m.abdelraheem@tudelft.nl (E.A.); Tel.: +31-15-2789304 (U.H.)

† These authors contribute equally in this work.

Abstract: DERA (2-Deoxy-D-ribose 5-phosphate aldolase) is the only known aldolase that accepts two aldehyde substrates, which makes it an attractive catalyst for the synthesis of a chiral polyol motif that is present in several pharmaceuticals, such as atorvastatin and pravastatin. However, inactivation of the enzyme in the presence of aldehydes hinders its practical application. Whole cells of *Pectobacterium atrosepticum* were reported to exhibit good tolerance toward acetaldehyde and to afford 2-deoxyribose 5-phosphate with good yields. The DERA gene (*Pa*DERA) was identified, and both the wild-type and a C49M mutant were heterologously expressed in *Escherichia coli*. The purification protocol was optimized and an initial biochemical characterization was conducted. Unlike other DERAs, which show a maximal activity between pH 4.0 and 7.5, *Pa*DERA presented an optimum pH in the alkaline range between 8.0 and 9.0. This could warrant its use for specific syntheses in the future. *Pa*DERA also displayed fourfold higher specific activity than DERA from *E. coli* (*Ec*DERA) and displayed a promising acetaldehyde resistance outside the whole-cell environment. The C49M mutation, which was previously identified to increase acetaldehyde tolerance in *Ec*DERA, also led to significant improvements in the acetaldehyde tolerance of *Pa*DERA.

Keywords: DERA; *Pectobacterium atrosepticum*; aldolase; acetaldehyde resistance

1. Introduction

Aldolases are a class of enzymes that catalyze aldol reactions between two carbonyl compounds. DERA (2-Deoxy-D-ribose 5-phosphate aldolase) occupies an important position in biological systems, since it is involved in the catabolism of nucleosides. Pentose phosphates (specifically ribose 5-phosphate (R5P) and 2-deoxyribose 5-phosphate (DR$_5$P)) are the building blocks of nucleosides and in turn also of ribonucleotides and deoxy ribonucleotides [1]. In 1951, Racker reported that cellular extracts of *E. scherichia coli* catalyze the reversible reaction of glyceraldehyde 3-phosphate (GAP) with acetaldehyde to give DR5P [2]. DERA has since been utilized as a biocatalyst for the synthesis of epothilones, which are inhibitors of microtubule function and as such show potential as anticancer drugs [3]. DERA has

also been utilized for the synthesis of different types of deoxysugars, such as deoxy-, dideoxy-, trideoxy-, aza- and thio sugars [4]. Additionally, DERA has provided a straightforward route toward pyrimidine nucleosides [5,6], 5-deoxy ketoses and nine carbon sialic acid-type sugar derivatives [7,8]. Most intriguingly, DERA can also catalyze sequential aldol reactions (Scheme 1) [9]. The sequential conversion of two acetaldehyde molecules is one of the most promising methods for the synthesis of statin side chains, creating both stereocenters in a single step [10–14]. Statins are drugs frequently prescribed to reduce LDL cholesterol blood levels by inhibiting the 3-hydroxy-3-methyl-glutaryl-CoA reductase. The recent application of DERA for the synthesis of islatravir demonstrates its potential in industry [15].

Scheme 1. *Pa*DERA C49M catalyzed sequential aldol reaction between three acetaldehyde molecules.

Yet, industrial scale applications of DERA have so far been limited due to its poor stability toward high concentrations of acetaldehyde and its derivatives. In addition, the catalytic efficiency for sequential aldol reactions with unnatural substrates is low. Valino et al. carried out a hierarchical screening of different bacteria to identify strains, which show DERA activity. In particular, *Pectobacterium atrosepticum* (formerly *Erwinia caratovora*) ATCC 33260, a Gram-negative phytopathogenic bacterium, was reported to efficiently synthesize DR5P from GAP and acetaldehyde in whole-cell bioconversions [5]. Here, we report the heterologous expression and characterization of *Pa*DERA and a C49M single mutant, which shows improved acetaldehyde tolerance. The properties of these variants were biochemically characterized and compared with *E. coli* DERA (*Ec*DERA).

2. Results

2.1. Identification of PaDERA

The *deoC* gene was amplified from the bacterial genome of *P. atrosepticum* and cloned into the pET-28a expression vector containing either an *N*– or *C*–terminal His$_6$-tag. *Pa*DERA was then heterologously expressed in *E. coli* BL21(DE3) and purified by affinity chromatography using *Ec*DERA as reference.

*Pa*DERA-*C*-His$_6$ contained two extra amino acids at the *N*-terminus and three extra amino acids as a spacer between the enzyme and the His$_6$-tag. In order to exclude any negative effects on the activity of *Pa*DERA, the *C*-terminally His$_6$-tagged protein was also produced without this small spacer (see Table S1). Pure DERAs were obtained by affinity chromatography according to SDS-PAGE analyses (Figure S5). The initial purification protocol involved a gradient elution (elution buffer: 1 M imidazole, pH 7 and running buffer: 100 mM KPi, pH 7), but several other proteins were obtained alongside our protein of interest (AC and AD lanes, Figure S5A). Consequently, the gradient elution step was replaced by several longer, isocratic elution steps with the same elution buffer and running buffer. After stepwise washing with 3 mL fractions of running buffer containing 0, 25, 50, 100 mM imidazole, enzyme was eluted from the column using fractions 3 mL purification buffer containing 250 mM

and 2 × 500 mM imidazole. This optimized elution protocol is shown in Figure S5B and SDS-PAGE analyses indicated an improved purification in the form of a sharp band for *Pa*DERA.

The activity of *Pa*DERA with the small spacer was found to be slightly higher than that of *Pa*DERA without the spacer, namely 13.7 U/mg and 13.0 U/mg, respectively. Therefore, from here on only *Pa*DERA-C-His$_6$, which includes the small spacer, is discussed. The data obtained using the enzyme without the spacer can be found in Table S2. *Pa*DERA was found to be fourfold more active than *Ec*DERA (3.5 U/mg). This demonstrates that *Pa*DERA is a promising new member of the DERA toolbox.

2.2. Characterization of PaDERA

The activity and stability of purified *Pa*DERA was investigated using a coupled enzymatic assay with DR5P as substrate. The kinetic behavior of *Pa*DERA toward DR5P can be described by the Michaelis–Menten kinetic parameters. *Pa*DERA and *Ec*DERA activity was measured over a range from 0 to 2 mM of DR5P and fitted using the Michaelis–Menten equation (Figure S3). The V_{max} of *Pa*DERA (17.67 ± 1.01 U/mg) for DR5P cleavage was found to be higher than that of *Ec*DERA (4.21 ± 0.21 U/mg) under the same conditions, while the catalytic efficiencies are comparable (39.1 ± 9.4 mM^{-1}s^{-1} for *Pa*DERA and 31.25 ± 11.7 mM^{-1}s^{-1} for *Ec*DERA, Table 1).

Table 1. Michaelis–Menten kinetic parameters of *Pa*DERA and *Ec*DERA *.

Enzyme	MW [a] (kDa)	K_M (mM)	V_{max} (U/mg)	k_{cat} (s^{-1})	k_{cat}/K_M (mM^{-1}s^{-1})
*Pa*DERA	28.858	0.22 ± 0.04	17.67 ± 1.01	8.50 ± 0.48	39.1 ± 9.4
*Ec*DERA	28.556	0.06 ± 0.02	4.21 ± 0.21	2.00 ± 0.10	31.25 ± 11.7

[a] calculated from the amino-acid sequence, * the standard reaction mixture contained 0–2 mM DR5P, 0.2 mM NADH, 3 U GDH, 11 U TPI and 10 µL DERA. The volume was made up to 1 mL with 100 mM TEA buffer, pH 7, 25 °C.

Subsequently, the thermostability of the different DERA enzymes was investigated. At 40 °C, *Pa*DERA retained up to 90% of its initial activity after 10 min of incubation, and 80% after 60 min, respectively (Figure 1). However, only 60% of its initial activity was retained after incubation at 50 °C for 10 min. Since *P. atrosepticum* is a mesophilic bacterium we assume that the loss of the activity above 60 °C as shown in Figure 1 is due to the protein denaturation. Notably, this behavior is similar to that of *H. influenza* DERA. On the other hand, *Ec*DERA fully retains its initial activity after incubation at 60 °C for 60 min.


Figure 1. Overview of residual activity after incubation of *Pa*DERA (red) and *Ec*DERA (blue) at different temperatures (20–80 °C) in TEA buffer (100 mM, pH 7.0) measured after 10 min (continuous lines) and 60 min (dotted lines) of incubation. The activity was measured using the standard assay procedure at 25 °C.

*Pa*DERA showed high activities at alkaline pH in glycine-NaOH or triethanolamine (TEA)buffer. The activity of *Pa*DERA was optimal between pH 8.0 and 9.0. *Ec*DERA showed a maximal activity in range pH 7.0–9.0 as shown in Figure 2.

Figure 2. Overview of relative activity of (**a**) *Pa*DERA and (**b**) *Ec*DERA at different pH values. The enzyme assay was performed using the standard assay procedure in the following buffers (100 mM): (1) Citrate (pH 4.2, 5.0 and 6.2), (2) KPi (pH 6.2, 7.0 and 8.2), (3) TEA (pH 7.0, 8.0 and 8.3) and (4) Glycine–NaOH (pH 8.6, 9.0, 10.0 and 10.6).

2.3. Acetaldehyde Tolerance of DERA Enzymes

A direct comparison of the acetaldehyde resistance of *Ec*DERA with *Pa*DERA was performed. An exponential decay of DERA activity was observed for both *Ec*DERA and *Pa*DERA in the presence of 100 mM of acetaldehyde (Figure 3). Interestingly, *Pa*DERA appears to be more tolerant toward high concentrations of acetaldehyde than *Ec*DERA, retaining 30% of its initial activity after 40 min of incubation. Under the same conditions, *Ec*DERA is completely inactivated after only 20 min [16].


Figure 3. DERA inactivation of the two variants *Pa*DERA (blue) and *Ec*DERA (red) upon incubation with 100 mM acetaldehyde at 25 °C in 100 mM TEA buffer pH 7.0. A specific activity of 11.9 U/mg for *Pa*DERA and 1.7 U/mg for *Ec*DERA were normalized at 100%.

For *Ec*DERA, the C47M mutation was reported to significantly improve acetaldehyde resistance, as it replaces a cysteine, that has been proposed to be involved in the deactivation mechanism [16]. *Ec*DERA Cys47 is conserved in *Pa*DERA and corresponds to Cys49. Moreover, the two sequences share

considerable identity around the Cys47/Cys49 position, as can be seen from the alignment in Figure S1. Therefore, the effect of the mutation C47M on *Pa*DERA was investigated. The *Pa*DERA C49M variant was expressed and purified following the same, approach as for the WT enzyme (Figures S4 and S5). The acetaldehyde resistance of the C49M mutant was evaluated by incubating the enzyme in the presence of 100 mM, 200 mM and 300 mM of acetaldehyde and measuring the residual activity at various time points using the coupled assay under standard conditions. In comparison to the wild-type enzyme, *Pa*DERA C49M showed excellent stability in the presence of up to 300 mM of acetaldehyde, where it retained 90% of its activity after incubation for 90 min (Figure 4). In contrast, wild-type *Pa*DERA lost 70% of its activity after incubation for 30 min in the presence of 100 mM acetaldehyde.


Figure 4. Time-dependent activity of *Pa*DERA C49M during incubation at different acetaldehyde concentrations (100 mM (blue), 200 mM (red) and 300 mM (green)) to estimate the residual activity using the standard assay protocol. The residual activity after incubation in the absence of acetaldehyde was 3.5 U/mg and was normalized to 100%.

Finally, the *Pa*DERA C49M variant was employed in the sequential aldol reaction for the enzymatic synthesis of 2,4,6-trideoxy-D-erythrohexapyranoside (Scheme 1). Whole cells of *E. coli* (3 mg/mL) containing the *Pa*DERA C49M variant were incubated with 100 mM of acetaldehyde for 48 h. The product was directly extracted from the reaction mixture and the yield of 50% was obtained without further purification. The product was confirmed by gas chromatography(GC), ^{1}H-NMR and ^{13}C-NMR spectroscopy (Figures S6 and S7) [17].

3. Discussion

One of the bottlenecks in the enzymatic synthesis of polyol motif synthons is represented by the poor stability of DERAs in acetaldehyde. For this reason, it is necessary to evaluate the synthetic performances of new DERA enzymes from different organisms. Here, the properties of DERA from *P. atrosepticum* (*Pa*DERA) were investigated.

Recombinant expression of *Pa*DERA was successfully demonstrated in *E. coli* and the enzyme was purified in a single chromatographic step. In order to allow direct comparison, the well-known enzyme from *E. coli* (*Ec*DERA) was locally produced and purified as well.

*Pa*DERA showed biochemical properties that are comparable to those of other members of the DERA family. While *Pa*DERA is stable at up to 40 °C, DERAs with a higher thermostability have been reported, e.g., DERAs from several strains including *Paenibacillus* sp. EA001, *Haloarcula japonica* and *Aciduliprofundum boonei* were shown to be highly stable after incubation at 50, 60 and 80 °C, respectively.

*Pa*DERA has an optimum pH in the basic range from 8.0 and 9.0, which is similar to DERAs from *E. coli* and *Salmonella typhimurium*. DERAs from *Thermococcus kodakaraensis*, *Lactobacillus brevis* and *Rhodococcus erythropolis* have been reported to have an optimum activity in acidic range 4.0 to 6.0 (Table S2). At pH 7 the activity in phosphate buffer was lower than in TEA buffer. Apparently

there is a buffer effect of either phosphate buffer or TEA buffer on DERA or the enzyme used in the coupled assay. We did not observe an effect of phosphate addition in independent enzyme assays with *Pa*DERA. To our knowledge no negative or positive effects of these buffer components on DERA have been reported previously. In our hands, the V_{max} of *Pa*DERA was circa fourfold higher than that of *Ec*DERA under identical assay conditions. However, previously reported kinetic parameters for *Ec*DERA (Table S2) are significantly higher than the values that were obtained here, with a K_M of 0.23–0.29 mM for DR5P and V_{max} of 58–85 U/mg, despite using highly similar assay conditions [18,19]. We do not have an explanation for the observed differences.

The tolerance of aldolases toward aldehyde substrates is important for the enzyme function and reaction efficiency. In this study, we showed that wild-type *Pa*DERA is more stable than wild-type *Ec*DERA in the presence of 100 mM of acetaldehyde. The C49M mutation further improved the aldehyde tolerance of *Pa*DERA. Surprisingly, its residual activity increased again after incubation for 60 min at 100 mM, 200 mM and 300 mM of acetaldehyde. This may be due to an increased carry-over of acetaldehyde to the enzyme assay mixture, which may affect the result of the coupled assay. *Ec*DERA C47M showed no loss of activity after incubation in 300 mM of acetaldehyde for 16 h. For *Ec*DERA, it has been reported that the product of the DERA catalyzed aldol reaction of acetaldehyde can undergo water elimination resulting in crotonaldehyde. Cysteine 47 reacts with the crotonaldehyde via a Michael addition, deactivating the enzyme. By replacing cysteine 47 with methionine this deactivation mechanism is suppressed [16].

Furthermore, the aldehyde tolerance of *Pa*DERA C49M is similar to that of T120C, G174I and G213C mutants of *Staphylococcus epidermidis* DERA, which was determined to be 70.5% under similar conditions (see Table S2) [20]. In contrast, wild-type *Ec*DERA was reported to be almost completely inactivated after incubation in 300 mM acetaldehyde for 3 h [16,18].

4. Materials and Methods

4.1. Chemicals

Each of 2-Deoxy-D-ribose 5-phosphate, DL-glyceraldehyde-3-phosphate and acetaldehyde were obtained from Sigma-Aldrich (Saint Louis, MS, USA). Acetaldehyde was of the highest analytical purity and it was purchased in small vials of 5 mL. Deionized water was used for all experiments. α-Glycerophosphate Dehydrogenase-Triose phosphate Isomerase (GDH-TPI) was obtained from Sigma-Aldrich. T4 DNA ligase and *Dpn*I were obtained from Biolabs. Phusion HS-II MM high-fidelity polymerase was obtained from Thermo Fischer Scientific.

4.2. Molecular Biology Methods

4.2.1. Cloning of DeoC *P. atrosepticum*

The *deo*C gene from *P. atrosepticum* ATCC 33.260 (Figure S1) encoding *Pa*DERA (NCBI Reference Sequence: WP_039289985) was cloned from the bacterial genome *Erwinia carotovora* into the expression vector pET-28 a (+) carrying the resistance to kanamycin. The deoC gene was amplified by polymerase chain reaction (PCR) in frame with N-terminal or C-terminal His-tag. The primers for the PCR contain a *NcoI* and *XhoI* site at the N– and C– terminus and are showed in Table S1. A PCR was done with the Phusion HS-II MM high-fidelity polymerase and a gel purification of the PCR product was performed to obtain pure *deo*C$_{Pa}$ DNA. The sequences of the obtained plasmids were analyzed by BaseClear (Leiden, The Netherlands).

4.2.2. Site-Directed Mutagenesis of *Pa*DERA

Mutant C49M was prepared using the QuikChange site-directed mutagenesis kit(Agilent Technologies, California, USA). A total reaction volume of 20 μL was used, containing approximately 5 ng template of deoxyribonucleic acid (DNA), 10 μL of DNA polymerase and reverse and forward

mutagenic primers 10 μM (each). The mutagenic primers are listed in Table S1. Gradient PCR program included 95 °C for 30 s; 32 cycles of 95 °C 30 s, 64–74 °C 30 s and 72 °C 2 min; 72 °C for 10 min. Ligation was carried out after PCR, 2 μL 10x T4 DNA ligase buffer and 1μL T4 DNA ligase were added to the PCR product and incubated at room temperature for 1 h. *DpnI* digestion was carried out to selectively digest the naturally methylated DNA template: 2 μL 10x NEB-buffer and 1 μL *DpnI* enzyme were added to the ligated PCR product and incubated for 4 h at 37 °C (Innova Incubator, Hamburg, Germany). Afterwards, the PCR product was transformed into *E. coli* TOP10 and grown in 5 mL LB-kan for 16 h at 37 °C. DNA plasmid was isolated using the mini prep kit (Qiagen, Hilden, Germany) from three isolated colonies and further quantified using a Nanodrop spectrophotometer (Thermo Fischer Scientific, Waltham, USA). Correct introduction of the mutation was confirmed by sequencing at BaseClear (Leiden, The Netherlands).

4.2.3. Protein Expression and Purification

Chemically competent *E. coli* BL21 (DE3) was transformed with the different plasmids according to the heat shock method. These transformants (10–100 μL) were plated on LB-agar containing 30 μg/mL kanamycin and incubated at 37 °C overnight. The preculture was prepared by picking individual colonies to inoculate a 10 mL LB medium containing 10 μg/mL kanamycin (kan) grown at 37 °C, 180 rpm overnight. The preculture was used to inoculate 1L LB medium containing 10 μg/mL kanamycin. Protein expression was induced at OD600 = 0.8–1.0 by the addition of isopropyl-β-d-thiogalactoside (IPTG) to a final concentration of 0.1 mM and cultures were grown overnight at 25 °C, 120 rpm. Cells were harvested by centrifugation at 4 °C, 8000 rpm for 15 min and were stored at −20 °C.

Cells were resuspended in buffer A (100 mM KPi, 0.5 mM NaCl, pH 7.0) to achieve an end concentration of 20% w/v. The resuspended cells were then disrupted on ice using Branson Sonifier 250 (Emerson Electric, St. Louis, USA) at a power output of 2 and 40% duty cycle for 15 min. The disrupted cells were centrifuged at 4 °C and 4000 rpm for 15 min and the cell free extract was obtained as the supernatant. A His-trap FF 1 mL column containing Ni^{2+}-NTA (Nickel-Nitrilotriacetic acid) (GE, Healthcare, New York, N.Y., USA) was used for all purifications. The column was first equilibrated with 3–5 column volumes of buffer A. It was then loaded with the cell free extract. The protein of interest was eluted from the column using buffer B (100 mM KPi, 1M Imidazole, 0.5 M NaCl, pH 7.0) in isocratic steps until the desired protein eluted at 50% buffer B. The purification was carried out on the NGC Chromatography System (BIORAD, Hercules, CA, USA). Relevant fractions of the eluted proteins were combined in a 10 kDa Amicon ultrafiltration tube (MilliporeSigma, MA, USA) and centrifuged at 4 °C and 4000 rpm till the volume was down to approximately 2.5 mL. The concentrated protein was desalted using a PD-10 column (GE, Healthcare, New York, NY, USA) and 2 mL, 100 mM KPi buffer pH 7.0.

4.3. Protein Analysis

The protein concentration was determined using the Bradford assay with BSA as a standard. SDS-PAGE was performed using 12% Bis-Tris precast gels running in 1x XT MES buffer, at 200 V for 40 min. The gel was stained using Simply Blue Safe Stain solution (Novex).

4.3.1. Activity Assay

DERA activity was measured using a coupled enzyme assay that has been reported previously [21]. DERA catalyzes the decomposition of 2-deoxy-D-ribose 5-phosphate to glyceraldehyde-3-phosphate and acetaldehyde. GAP is reduced to glycerol 3-phosphate by the enzymes α-glycerophosphate dehydrogenase (GDH) and triosephosphate isomerase (TPI). This reaction is monitored via the simultaneous oxidation of nicotinamide adenine dinucleotide (NADH). The activity of *Pa*DERA is determined by analyzing the consumption of NADH. One unit of aldolase was defined as the amount of enzyme able to catalyze the cleavage of 1.0 μmol of substrate (DR5P) per minute.

In a 2.5 mL PMMA cuvette, 0.2 mM NADH, 0.4 mM DR5P, 3U GDH, 11U TPI and 10 µL of protein sample were mixed. The volume was made up to 1 mL using 100 mM triethanolamine buffer (TEA) at pH 7.0 and the absorbance of NADH consumption was monitored for 1 min at 25 °C and 750 rpm. The temperature and stirring speed were controlled using the TC1 Temperature Controller (Quantum Northwest, Liberty Lake, Washington, USA) (Company, City, State Abbr. (if has), Country) and absorbance measurements were detected at 340 nm using the Cary 60 UV-Vis Spectrophotometer (Agilent Technologies, California, USA) (Company, City, State Abbr. (if has), Country).

4.3.2. Determination of pH and Temperature Optima and Kinetic Parameters

The optimum pH was determined using the standard activity assay of the purified enzyme (1 mg/mL) at different buffers (100 mM) in the pH range from 4 to 11: Sodium citrate (pH 4.2, 5 and 6.2), potassium phosphate (pH 6.2, 7.0 and 8.2), triethanolamine (pH 7.0, 8 and 8.3) and glycine–NaOH (pH 8.6, 9.0, 10.0 and 10.6). For the determination of the temperature optima, purified enzyme (1 mg/mL) was incubated at various temperatures between 20 °C and 80 °C in 10 °C increments. Samples were taken at two different time points 10 and 60 min (see Figure 1) and residual activity was measured using the coupled enzyme assay described above. Non-incubated enzyme was taken as a control. To obtain the Michaelis–Menten kinetic parameters, the activity assay was performed as described above for various substrate DR5P concentrations. The standard reaction mixture contained a particular concentration of DR5P, 0.2 mM NADH, 3 U GDH, 11 U TPI and 10 µL DERA. The volume was made up to 1 mL with TEA buffer. All measurements were performed in duplicate. Data fitting was done using Prism (GraphPad) (GraphPad Software Inc., California, USA).

4.3.3. Acetaldehyde Resistance of DERA

The purified enzyme (1 mg/mL) was incubated at 25 °C in 100 mM, 200 mM or 300 mM of 99.5% pure acetaldehyde obtained from Sigma-Aldrich chemicals. Samples were drawn at 20, 45, 60 and 90 min and residual activity was measured using the coupled enzyme assay as described above. Enzyme that was incubated at 25 °C in the absence of acetaldehyde was taken as a control (0 min).

4.3.4. Sequential Aldol Reaction

The reaction was carried out using 3 mg/mL *Pa*DERA expressing whole cells, 100 mM TEA buffer pH 7.0 acetaldehyde 100 mM in a total volume of 10 mL. The reaction was stirred at 30 °C for 48 h. The reaction was extracted with ethyl acetate and dried over anhydrous Na_2SO_4. The solvent was evaporated. The crude lactol was purified by silica column chromatography (BÜCHI LABORTECHNIK AG, Flawil, Switzerland) with EtOAc: Pet. Ether (30:70) as an eluent yielding pure 2,4,6-trideoxy-D-erythrohexapyranoside and subjected to GC (GC-2014, Shimadzu, Kyoto, Japan), ^{1}H NMR and ^{13}C NMR (Figure S7) (Agilent Technologies, California, USA) (Company, City, State Abbr. (if has), Country); ^{1}H NMR (400 MHz, Chloroform-d) δ 5.31 (d, J = 5.0 Hz, 1H, α), 5.15 (br, 1H, β), 4.41 (dtd, J = 12.4, 6.2, 2.3 Hz, 1H, α), 4.31 (s, 1H, β), 4.21 (dt, J = 6.7, 3.5 Hz, 1H, α), 4.05 (q, J = 6.2, 5.7 Hz, 1H, β), 3.11 (br, 1H, β), 3.01 − 2.97 (m, 1H, α), 2.03 − 1.91 (m, 2H, β), 1.80 (ddp, J = 11.7, 6.0, 3.0 Hz, 2H, α), 1.66 − 1.58 (m, 2H, β), 1.52 (dddd, J = 14.1, 11.7, 5.9, 2.4 Hz, 2H, α), 1.24 (s, 1H, β), 1.20 (t, J = 6.2 Hz, 3H, α); ^{13}C NMR (101 MHz, Chloroform-d) α anomer δ 93.0, 65.1, 58.9, 39.9, 34.9, 21.5. β anomer δ 92.3, 66.6, 65.6, 39.6, 39.5, 21.4 in accordance with literature [17].

5. Conclusions

In summary, the new improved *Pa*DERA C49M was successfully introduced as a biocatalyst for the sequential aldol reaction with high substrate loading. Both variants *Pa*DERA and *Pa*DERA C49M were purified and characterized. *Pa*DERA has a basic pH optimum and a high acetaldehyde tolerance. Overall, this study shows that *Pa*DERA is a promising new member that can be added to the DERA toolbox.

6. Patents

There are no patents resulting from the work reported in this manuscript.

References

1.　Salleron, L.; Magistrelli, G.; Mary, C.; Fischer, N.; Bairoch, A.; Lane, L. DERA is the human deoxy ribose phosphate aldolase and is involved in stress response. *Biochim. Biophys. Acta Mol. Cell Res.* **2014**, *1843*, 2913–2925. [CrossRef] [PubMed]

2.　Racker, E. Enzymatic synthesis of deoxy pentose phosphate. *Nature* **1951**, *167*, 408–409. [CrossRef] [PubMed]

3.　Liu, J.; Wong, C.-H. Aldolase-Catalyzed Asymmetric Synthesis of Novel Pyranose Synthons as a New Entry to Heterocycles and Epothilones. *Angew. Chem. Int. Ed.* **2002**, *41*, 1404–1407. [CrossRef]

4.　Barbas, C.F.; Wang, Y.F.; Wong, C.H. Deoxyribose-5-phosphate aldolase as a synthetic catalyst. *J. Am. Chem. Soc.* **1990**, *112*, 2013–2014. [CrossRef]

5.　Valino, A.L.; Iribarren, A.M.; Lewkowicz, E. New biocatalysts for one pot multistep enzymatic synthesis of pyrimidine nucleoside diphosphates from readily available reagents. *J. Mol. Catal. B Enzym.* **2015**, *114*, 58–64. [CrossRef]

6.　Valino, A.L.; Palazzolo, M.A.; Iribarren, A.M.; Lewkowicz, E. Selection of a new whole cell biocatalyst for the synthesis of 2-deoxyribose-5-phosphate. *Appl. Biochem. Biotechnol.* **2012**, *166*, 300–308. [CrossRef] [PubMed]

7.　Gijsen, H.J.M.; Wong, C.-H. Unprecedented Asymmetric Aldol Reactions with Three Aldehyde Substrates Catalyzed by 2-Deoxyribose-5-phosphate Aldolase. *J. Am. Chem. Soc.* **1994**, *116*, 8422–8423. [CrossRef]

8.　Gijsen, H.J.M.; Wong, C.-H. Sequential one-pot aldol reactions catalyzed by 2-deoxyribose-5-phosphate aldolase and fructose-1,6-diphosphate aldolase. *J. Am. Chem. Soc.* **1995**, *117*, 2947–2948. [CrossRef]

9.　Gijsen, H.J.M.; Wong, C.-H. Sequential three- and four-substrate aldol reactions catalyzed by aldolases. *J. Am. Chem. Soc.* **1995**, *117*, 7585–7591. [CrossRef]

10.　Machajewski, D.T.; Wong, C.-H. The catalytic Asymmetric Aldol Reaction. *Angew. Chem. Int. Ed.* **2000**, *39*, 1352. [CrossRef]

11.　Xuri, W.; Jinpeng, J.; Yijun, C. Correlation between Intracellular Cofactor Concentrations and Biocatalytic Efficiency: Coexpression of Diketoreductase and Glucose Dehydrogenase for the Preparation of Chiral Diol for Statin Drugs. *ACS Catal.* **2011**, *1*, 1661.

12.　Haridas, M.; Abdelraheem, E.M.M.; Hanefeld, U. 2-Deoxy-D-ribose-5-phosphate aldolase (DERA): Applications and modifications. *Appl. Microbiol. Biotechnol.* **2018**, *102*, 9959–9971. [CrossRef] [PubMed]

13.　Gijsen, H.J.M.; Qiao, L.; Fitz, W.; Wong, C.-H. Recent Advances in the Chemoenzymatic Synthesis of Carbohydrates and Carbohydrate Mimetics. *Chem. Rev.* **1996**, *96*, 443–473. [CrossRef] [PubMed]

14.　Schürmann, M. An Aldolase for the synthesis of the statin side chain. In *Industrial Enzymes Applications*; Wiley-VCH: Weinheim, Germany, 2019; pp. 385–403.

15. Huffman, M.A.; Fryszkowska, A.; Alvizo, O.; Borra-Garske, M.; Campos, K.R.; Canada, K.A.; Devine, P.A.; Duan, D.; Forstater, J.H.; Grosser, S.T.; et al. Design of an in vitro biocatalytic cascade for the manufacture of islatravir. *Science* **2019**, *366*, 1255–1259. [CrossRef] [PubMed]

16. Dick, M.; Hartmann, R.; Weiergräber, O.H.; Bisterfeld, C.; Classen, T.; Schwarten, M.; Neudecker, P.; Willbold, D.; Pietruszka, J. Mechanism-based inhibition of an aldolase at high concentrations of its natural substrate acetaldehyde: Structural insights and protective strategies. *Chem. Sci.* **2016**, *7*, 4492–4502. [CrossRef] [PubMed]

17. Abate, A.; Brenna, E.; Costantini, A.; Fuganti, C.; Gatti, F.G.; Malpezzi, L.; Serra, S. Enzymatic Approach to Enantiomerically Pure 5-Alken-2,4-diols and 4-Hydroxy-5-alken-2-ones: Application to the Synthesis of Chiral Synthons. *J. Org. Chem.* **2006**, *71*, 5228–5240. [CrossRef] [PubMed]

18. Sakuraba, H.; Yoneda, K.; Yoshihara, K.; Satoh, K.; Kawakami, R.; Uto, Y.; Tsuge, H.; Takahashi, K.; Hori, H.; Ohshima, T. Sequential aldol condensation catalyzed by hyperthermophilic 2-deoxy-d-ribose-5-phosphate aldolase. *Appl. Environ. Microbiol.* **2007**, *73*, 7427–7434. [CrossRef] [PubMed]

19. Kullartz, I.; Pietruszka, J. Cloning and characterisation of a new 2-deoxy-d-ribose-5-phosphate aldolase from *Rhodococcus erythropolis*. *J. Biotechnol.* **2012**, *161*, 174–180. [CrossRef] [PubMed]

20. Fei, H.; Xu, G.; Wu, J.-P.; Yang, L.-R. Improving the acetaldehyde tolerance of DERASEP by enhancing the rigidity of its protein structure. *J. Mol. Catal. B Enzym.* **2015**, *116*, 148–152. [CrossRef]

21. Nicholas, P.C. Determination of fructose-1,6-diphosphate aldolase activity with glyceraldehyde-3-phosphate dehydrogenase and diformazan formation. *Biochem. Soc. Trans.* **1988**, *16*, 753–754. [CrossRef]